tbuckley/cabot-search huggingface dataset:
FRANCE
Journal: JAMA (1963)

<h3>Cyclophosphamide in Cancer Diagnosis.</h3> —G. Riffat et al (<i>Lyon Med</i><b>209</b>:1523 [June 23] 1963) published a preliminary paper on the use of a derivative of mechlorethamine hydrochloride which has a strong cytoxic power, in the diagnosis of cancer. This compound causes, in the cells, lesions by way of mitosis, which are comparable to those of ionizing radiation. The authors noticed a difference between the subjects with cancer and the healthy subjects in their reactions to the drug. It was found that cyclophosphamide does not only attack tumor cells, but also the leukocytes. The concept of the authors is as follows: in cancer, cyclophosphamide acts first on the neoplastic tissues that are in a state of active multiplication, but if no cancer is present the leukocytes are the most active cells that can be affected. Because the average period of survival of the polymorphonuclear leukocytes is 70 or 80 hours,
Malignant hyperpyrexia.
Authors: N P Keaney, F R Ellis
Journal: BMJ (1971)

fill this seat, the choice lies between a career grade officer, a general practitioner, or a hospital junior doctor with a number of house appointments behind him.If staffing is to be entirely by career grade officers, then the minimum number is five and not four as suggested by Mr. F. C. Durbin and Mr. J. S. Batchelor (14 August, p. 432).To staff with only four would mean a 42-hour week without taking into account time for handing over between shifts, holidays, study leave, or sickness.For these career grade officers, there is need for consultant pay without specialist
SCIENTIFIC EXHIBITS
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Impedance Plethysmography and DVT Diagnosis
Authors: David R. Anderson
Journal: Annals of Internal Medicine (1993)

Letters1 August 1993Impedance Plethysmography and DVT DiagnosisDavid R. Anderson, MD, Anthonie Lensing, MD, and Jack Hirsh, MDDavid R. Anderson, MDSearch for more papers by this author, Anthonie Lensing, MDSearch for more papers by this author, and Jack Hirsh, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-119-3-199308010-00019 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Despite the letters of criticism, we contend that the low observed sensitivity of IPG for the diagnosis of proximal DVT in symptomatic outpatients is valid. The study venographic criteria are widely accepted [1-3]. The one patient diagnosed with DVT on the basis of non-filling of the proximal leg veins had abnormal compression ultrasound results. Analysis using only thrombi diagnosed by intraluminal filling defects on venography yields an IPG sensitivity for proximal DVT of 64% (30 of 47 patients) and a positive predictive value of 63% (30 of 48 patients).Duplex ultrasound is a highly sensitive test for proximal ...References1. Lensing AW, Prandoni P, Brandjes D, Huisman PM, Vigo M, Tomasella G, et al. Detection of deep-vein thrombosis by real-time B-mode ultrasonography. New Engl J Med. 1989; 320:342-5. Google Scholar2. Davidson BL, Elliott CG, Lensing AW, for the RD Heparin Arthroplasty Group. Low accuracy of color Doppler ultrasound in the detection of proximal leg vein thrombosis in asymptomatic high-risk patients. Ann Intern Med. 1992; 117:735-8. Google Scholar3. Ginsberg JS, Caco CC, Brill-Edwards P, Panju AA, Bona R, Demers CM, et al. Venous thrombosis in patients who have undergone major hip or knee surgery: detection with compression ultrasound and impedance plethysmography. Radiology. 1991; 181:651-4. Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 August 1993Volume 119, Issue 3Page: 246-247KeywordsDoppler imagingHipOutpatientsPositive predictive valueQuality improvementSurgeryUltrasound imagingVeins ePublished: 15 August 2000 Issue Published: 1 August 1993 Copyright & PermissionsCopyright © 1993 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Panel OKs CAR T Therapy for Leukemia
Journal: Cancer Discovery (2017)

Abstract An expert panel recommended approval of Novartis's experimental chimeric antigen T-cell therapy, tisagenlecleucel, for children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia. The therapy would be the first of its kind approved for cancer and has the potential to transform standard of care for advanced blood cancers.
Association of <i>RB1</i> mutational status with overall genomic landscape in neuroendocrine prostate cancer (NEPC).
Authors: Petros Grivas, Gennady Bratslavsky, Joseph M Jacob, Oleksandr Kravtsov, Andrea Necchi, Philippe E. Spiess, Natalie Danziger, Douglas I. Lin, Richard S.P. Huang, Vamsi Parini, Brennan Decker, Ethan Sokol, Hanna Tukachinsky, Mia Alyce Levy, Jeffrey S. Ross
Journal: Journal of Clinical Oncology (2022)

156 Background: NEPC is a high-grade aggressive form of prostate cancer. We queried whether RB1 mutation status would impact the genomic features of NEPC. We hypothesized that there would be differences in GA frequencies in RB1 mutated vs non mutated cases. Methods: From a series of 13,496 cases of clinically advanced PC, 415 (3.1%) histologically defined NEPC were sequenced using a hybrid capture-based FDA-approved clinical genomic profiling (CGP) assay to detect all classes of genomic alterations (GA). Tumor mutational burden (TMB) was determined on 0.8 Mbp of sequenced DNA and microsatellite instability (MSI) was determined on 95 loci. PD-L1 expression was determined by IHC (Dako 22C3) with low tumor cell positive staining 1-49% and high staining ≥50% expression. Results: 253 (61%) of NEPC feature GA in RB1 (RB1 mut+). This contrasts with a 5.8% frequency of RB1 GA in the non-NEPC (P &lt;.0001). The RB1 mut+ NEPC featured a slightly greater number of driver GA/tumor than the RB1 mut- NEPC (5.1 vs 4.2). Age and TMPRSS2-ERG fusion frequency were similar between the groups. RB1 Mut- NEPC was associated with significantly higher amplifications (amp) and total GA in AR compared to RB1 mut+ NEPC. RB1 mut+ NEPC featured significantly greater frequency of PTEN GA. GA frequencies in targetable kinases and DNA repair GA including BRCA1/2 and ATM linked to PARP inhibitor (PARPi) response were similar in both groups. For potential immune-oncology (IO) biomarkers, RB1 Mut+ NEPC featured significantly greater frequency of low positive PD-L1 expression and lower frequencies of MDM2 and CDK12 GA. CD274 ( PD-L1) amplification, MSI-high status and cases with TMB ≥10 mut/Mb were very uncommon in both groups. Conclusions: In NEPC, the presence of RB1 mutation is associated with various GA that may have clinical relevance. Limitations include possible selection and confounding biases, and lack of clinical annotation. Further study of RB1 status as a guide of trial designs on therapy selection for men with NEPC is warranted.[Table: see text]
Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open‐label study
Authors: David J. Kuter, Kerry A. Rogers, Michael A. Boxer, Michael Choi, Richy Agajanian, Donald M. Arnold, Catherine M. Broome, Joshua J. Field, Irina Murakhovskaya, Robert Numerof, Sandra Tong
Journal: American Journal of Hematology (2022)

Abstract Patients with relapsed warm antibody autoimmune hemolytic anemia (wAIHA) have limited treatment options. Fostamatinib is a potent, orally administered spleen tyrosine kinase inhibitor approved in the United States and Europe for the treatment of adults with chronic immune thrombocytopenia (ITP). This phase 2 study evaluated the response to fostamatinib, administered at 150 mg BID orally with or without food in adults with wAIHA and active hemolysis with hemoglobin (Hgb) &lt;10 g/dL who had failed at least one prior treatment. Hemoglobin levels and safety assessments were performed at visits every 2 weeks. The primary endpoint was Hgb &gt;10 g/dL with an increase of ≥2 g/dL from baseline by week 24 without rescue therapy or red blood cell transfusion. Eleven of 24 (46%) patients achieved the primary endpoint. Increases in median Hgb were detected at week 2 and sustained over time. Median lactate dehydrogenase levels and reticulocyte counts generally declined over time with little change in median haptoglobin levels. The most common adverse events (AEs) were diarrhea (42%), fatigue (42%), hypertension (27%), dizziness (27%), and insomnia (23%). AEs were manageable and consistent with the fostamatinib safety database of over 3900 patients across multiple diseases (rheumatoid arthritis, B‐cell lymphoma, COVID‐19, and ITP). No new safety signals were detected. Fostamatinib may be a promising therapeutic option for wAIHA. A randomized, double‐blind, phase 3 study is nearing completion.
Social and Physical Environment Inequalities and Childhood Health—Reply
Authors: Natalie Slopen, Nia Heard-Garris
Journal: JAMA Pediatrics (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Medico-Chirurgical Transactions.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CYCLONE 2: A phase 2/3, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer.
Authors: Matthew Raymond Smith, Neeraj Agarwal, Tilman Todenhöfer, Josep M. Piulats, Jae-Lyun Lee, Redas Trepiakas, Arpit Rao, Lisa Horvath, Andrew Lithio, Erica L. Johnston, Maarten Hulstijn, Karim Nacerddine, Christopher Sweeney
Journal: Journal of Clinical Oncology (2022)

TPS198 Background: Despite recent advances, nearly all patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) experience disease progression and cancer-specific mortality. Persistent or reactivated androgen receptor (AR) signaling and/or activation of pathways in cross-talk with AR signaling are key drivers of mCRPC progression. Evidence suggests that AR signaling promotes translation of D-type cyclins resulting in cyclin-dependent kinase 4 and 6 (CDK4&amp;6) activation and cell cycle progression. Abemaciclib is an oral selective inhibitor of CDK4&amp;6 dosed on a continuous schedule, that is FDA-approved in combination with endocrine therapy or as monotherapy to treat HR+, HER2- metastatic breast cancer pts. Preclinical studies with prostate cancer cell lines and xenograft models showed that abemaciclib induces cell cycle arrest and tumor growth inhibition. The hypothesis is that addition of abemaciclib to AR targeted therapy may be an effective treatment for mCRPC pts. Methods: CYCLONE 2 (NCT03706365) is a phase 2/3, randomized, double-blind, multicenter, placebo-controlled study to assess the safety and efficacy of abemaciclib in combination with abiraterone acetate plus prednisone (AA+P) in pts with mCRPC. CYCLONE 2 is an adaptive study which is designed in three parts. Part 1 is a 30-patient safety lead-in to determine the recommended phase 2 dose (RP2D; 150 mg or 200 mg, twice daily) of abemaciclib in combination with AA (1000 mg, once daily) + P (5 mg, twice daily). In part 2, 150 pts are randomized 1:1 to AA+P with abemaciclib at the RP2D or placebo. The study expands to enroll an additional 170 pts in Part 3 if prespecified expansion criteria are met at a planned adaptive interim analysis performed by an independent data monitoring committee (IDMC). Pts with mCRPC evidenced by radiographic and/or PSA progression during continuous ADT are eligible. Prior docetaxel for mHSPC is permitted. Systemic anti-cancer therapy for mCRPC and prior novel hormonal agents are exclusionary. The primary objective is radiographic progression free survival (rPFS; per RECIST1.1 for soft tissue and PCWG3 for bone). Secondary objectives include safety, objective response rate, duration of response, time to symptomatic and PSA progression, overall survival, and pharmacokinetics. Status: Enrollment in Part 1 &amp; 2 is completed. Based on the recommendation from the IDMC, Part 3 was opened in June 2021 and enrolls pts from about 112 sites across 12 countries. Clinical trial information: NCT03706365.
Locum consultants.
Authors: D E Bolt
Journal: BMJ (1978)

This situation occurs because points for medical problems contribute little to the points total.Data from six housing authorities in Wales (see table) that use the points system show that the total number of points which can be granted on medical grounds, and therefore the effectiveness of normal medical intervention, varies markedly.'Within these authorities the maximum number of medical points attainable as a percentage of the lowest Vaclue of miiedical points in relati'oni to qucallfing thrXeslhold for rehousislg in six housing authorities in lt"ales* Qualifying Maximum Maximum threshold medical Housinig illedical for points aulthorit!
Correction
Journal: BMJ (1950)

ANY QUESTIONS?by a well-fitting spinal support, or (2) to excise appropriate segments of the affected ribs.The benefit to be expected from these measures has to be balanced against the discomfort of wearing a rigid corset or the inconvenience of operation.Treatment should be advised only when the condition is the cause of quite significant disability.In the particular case mentioned it seems probable that the wisest course would be to accept the disability.
Review of Reviews
Authors: C D Leake
Journal: The Annual Review of Pharmacology and Toxicology (1976)

Heme oxygenases (HO) catabolize free heme, that is, iron (Fe) protoporphyrin (IX), into equimolar amounts of Fe2+, carbon monoxide (CO), and biliverdin. The stress-responsive HO-1 isoenzyme affords protection against programmed cell death. The mechanism ...Read More
Targeting the Ubiquitin–Proteasome System Using the UBA1 Inhibitor TAK-243 is a Potential Therapeutic Strategy for Small-Cell Lung Cancer
Authors: Safa Majeed, Mansi K. Aparnathi, Kevin C.J. Nixon, Vidhyasagar Venkatasubramanian, Fariha Rahman, Lifang Song, Jessica Weiss, Ranya Barayan, Vijithan Sugumar, Samir H. Barghout, Joel D. Pearson, Rod Bremner, Aaron D. Schimmer, Ming S. Tsao, Geoffrey Liu, Benjamin H. Lok
Journal: Clinical Cancer Research (2022)

Small cell lung cancer (SCLC) is an aggressive disease with an overall five-year survival rate of &lt;10%. Treatment for SCLC with cisplatin/etoposide chemotherapy (C/E) +/- radiotherapy (RT) has changed modestly over several decades. The ubiquitin-proteasome system is an underexplored therapeutic target for SCLC. We preclinically evaluated TAK-243, a first-in-class small molecule E1 inhibitor against UBA1.We assessed TAK-243 in 26 SCLC cell-lines as monotherapy and combined with C/E, the PARP-inhibitor, olaparib, and with radiation (RT) using cell viability assays. We interrogated TAK-243 response with gene expression to identify candidate biomarkers. We evaluated TAK-243 alone and in combination with olaparib or RT with SCLC patient-derived xenografts (PDX).Most SCLC cell-lines were sensitive to TAK-243 monotherapy (EC50 median 15.8nM, range 10.2nM - 367.3nM). TAK-243 sensitivity was associated with gene-sets involving the cell cycle, DNA and chromatin organization, and DNA damage repair, while resistance associated with cellular respiration, translation, and neurodevelopment. These associations were also observed in SCLC PDXs. TAK-243 synergized with C/E and olaparib <em>in vitro</em> across sensitive and resistant SCLC cell-lines. Considerable TAK-243-olaparib synergy was observed in an SCLC PDX resistant to both drugs individually. TAK-243 radiosensitization was also observed in an SCLC PDX.TAK-243 displays efficacy in SCLC preclinical models. Enrichment of gene-sets is associated with TAK-243 sensitivity and resistance. TAK-243 exhibits synergy when combined with genotoxic therapies in cell-lines and PDXs. TAK-243 is a potential therapeutic strategy to improve SCLC patient outcomes, both as a single agent and in combination with existing therapies.
Acute epiglottitis.
Authors: M. K. Hudson
Journal: BMJ (1968)

months the patient had been taking Distalgesic (dextropropoxyphene with paracetamol) for interittent headaches, and estimated her intake to be approximately six tablets per week.With no other significant history she presented with thrombocytopenic purpura.Physical examination and all laboratory investigations failed to reveal any underlying cause.The patient's platelet count rose spontaneously to 142,000/ cu.mm. after seven days, and with a provisional
Health Agencies Update
Authors: Joan Stephenson
Journal: JAMA (1997)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction
Journal: BMJ (1959)

Any Questions ?We publish below a selection of those questions and answers which seem of general interest.It is regrette(d that it is not possible to supply answers to all questions si'bmitted.B.C.G.Vaccination in Pregnancy Q.-Is there any danger in giving B.C.G. to a pregnant woinan with a negative Mantoux?A.-There is no danger in inoculating a Mantoux-negative pregnant woman with B.C.G.In fact, this has often been done without any harm to either mother or foetus. Corticosteroids in Disseminated SclerosisQ.-What is the value of A.C.T.H., cortisone, or prednisone in the treatment of acute episodes in disseminated sclerosis?Which is the drug of choice?In what dosage, and for how long, should it be given ?A.-Any conclusions about whether A.C.T.H. or cortisone